Q3 2025 Financial Performance - Revenues increased by 12% year-over-year, reaching $9557 million in Q3 2025, compared to $8503 million in Q3 2024[12] - Product sales also increased by 12% year-over-year, totaling $9137 million in Q3 2025, up from $8151 million in Q3 2024[12] - The company invested $1900 million in Research and Development (R&D) in Q3 2025, which is a 31% increase compared to $1440 million in Q3 2024[12] - Non-GAAP EPS increased by 1% to $564 in Q3 2025 from $558 in Q3 2024[12] - Free cash flow increased to $42 billion in Q3 2025, compared to $33 billion in Q3 2024[14] Product Performance - Repatha sales increased by 40% year-over-year to $794 million in Q3 2025[20] - EVENITY sales increased by 36% year-over-year to $541 million in Q3 2025[20] - TEZSPIRE sales increased by 40% year-over-year to $377 million in Q3 2025[20] - UPLIZNA sales increased by 46% year-over-year to $155 million in Q3 2025[20] 2025 Guidance - The company revised its revenue guidance for 2025 to $358 billion - $366 billion, up from the previous guidance of $350 billion - $360 billion[16]

Core Viewpoint - Amgen is set to report its third quarter 2025 financial results on November 4, 2025, followed by a conference call with senior management to discuss the results and engage with the investment community [1]. Financial Results Announcement - The financial results will be announced after the close of U.S. financial markets on November 4, 2025 [1]. - A conference call will take place at 4:30 p.m. ET, featuring Robert A. Bradway, chairman and CEO, along with other senior management members [1]. Conference Call Details - The conference call will be broadcast live over the internet, accessible to media, investors, and the general public [2]. - The webcast will be archived and available for replay for at least 90 days post-event [3]. Company Overview - Amgen is a biotechnology company focused on discovering, developing, manufacturing, and delivering innovative medicines for serious diseases [4]. - The company has a strong pipeline aimed at treating various conditions, including cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [4]. Recognition and Market Position - In 2024, Amgen was recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes [5]. - Amgen is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its significant market presence [5].

Financial Performance - Revenues increased by 9% YoY in Q2 2025, reaching $9.179 billion, with product sales contributing $8.771 billion[9, 105] - Non-GAAP EPS grew by 21% YoY in Q2 2025, reaching $6.02[9, 105] - The company invested $1.7 billion in research and development in Q2 2025, an increase of 18% YoY[9] - Free cash flow was $1.9 billion in Q2 2025, compared to $2.2 billion in Q2 2024[107] Product Sales Highlights - Fifteen products achieved double-digit sales growth, including Repatha, EVENITY, IMDELLTRA, BLINCYTO, TEZSPIRE, UPLIZNA, and TAVNEOS[9, 17] - Repatha sales increased by 31% YoY to $696 million, driven by a 36% increase in volume[12, 23] - EVENITY sales increased by 32% YoY to $518 million, primarily driven by volume growth[12, 23] - UPLIZNA sales increased by 91% YoY to $176 million, driven by 79% volume growth[12, 27] - TEZSPIRE sales increased by 46% YoY to $342 million, driven by volume growth[12, 32] - IMDELLTRA generated $134 million in sales, with a 65% quarter-over-quarter increase[12, 37] Pipeline Development - MariTide: Phase 3 studies are enrolling for obesity and overweight, with or without Type 2 diabetes mellitus, and for adults living with heart failure with preserved or mildly reduced ejection fraction and obesity[42] - UPLIZNA: FDA review of Phase 3 data in generalized myasthenia gravis is ongoing, with a PDUFA date of December 14, 2025[46] - TEZSPIRE: FDA review of Phase 3 data in chronic rhinosinusitis with nasal polyps is ongoing, with a PDUFA date of October 19, 2025[59] - IMDELLTRA: Reduced the risk of death by 40% and significantly extended median OS by more than five months compared to SOC chemotherapy in patients with SCLC who progressed on or after one line of platinum-based chemotherapy[71]

Q1 2025 Financial Performance - Total revenue increased by 9% year-over-year, reaching $8.149 billion[97] - Product sales increased by 11% year-over-year, totaling $7.873 billion[97] - Non-GAAP EPS increased by 24% year-over-year, reaching $4.90[97] - Research and development investment increased by 12% year-over-year, reaching $1.5 billion[9] - Free cash flow was $980 million in Q1 2025, compared to $459 million in Q1 2024[117] Product Performance Highlights - Repatha sales increased by 27% year-over-year, reaching $656 million, driven by 41% volume growth[12, 22] - EVENITY sales increased by 29% year-over-year, reaching $442 million, driven by volume growth[12, 22] - Prolia sales increased by 10% year-over-year, reaching $1.099 billion, driven by 13% volume growth[12, 22] - TEZSPIRE sales increased by 65% year-over-year, reaching $285 million, driven by volume growth[12, 32] - BLINCYTO sales increased by 52% year-over-year, reaching $370 million, primarily driven by volume growth[12, 37] - IMDELLTRA generated $81 million in sales in Q1 2025[12, 17, 37] Pipeline and Regulatory Updates - FDA approved UPLIZNA for the treatment of IgG4-RD in adult patients[9, 51] - Positive Phase 3 data from IMDELLTRA, UPLIZNA, and rocatinlimab[9] - Initiated multiple Phase 3 trials of MariTide and TEZSPIRE[9] - The company expects 2025 revenue to be in the range of $34.3 billion to $35.7 billion[101]